Mineral and Vitamin Supplements

Zana Dragidella^*
*Correspondence: Zana Dragidella, Department of Food Science and Nutrition, Faculty of Health Sciences, The Public Authority for Applied Education and Training, AlFaiha 72853, Kuwait, Email:

Introduction

In the United States, 40–50 of the men and women 50 times of age or aged regularly use multivitamin/mineral (MVM) supplements, making the periodic deals of these supplements over$ 11 billion. Still, the question remains whether using MVM supplements is salutary to health. This composition reviews the results of randomized studies of MVM supplements and individual vitamins mineral supplements in relation to overall mortality and prevalence of habitual conditions, particularly cancer and ischemic heart complaint. The results of large-scale randomized trials show that, for the maturity of the population, there's no overall benefit from taking MVM supplements. Indeed, some studies have shown increased threat of cancers in relation to using certain vitamins.

Description

Multivitamin/mineral (MVM) supplements clearly vend well in the United States. According to the National Health and Nutrition Examination Survey (NHANES) data, collected between 2003 and 2006, 40–50 of the men and women 50 times of age or aged regularly consume MVM 0 supplements. In 2009, the total trade of nutritive supplements in the United States was roughly $27 billion and in 2010, despite the profitable downturn, this number grew by 4.4 to over $28 billion. Of this, over $11 billion were the deals of MVM or MVM- containing supplements. Still, do healthy individualities really need MVM supplements? Are they salutary in reducing the threat of habitual conditions similar as ischemic heart complaint, cancer, and stroke? The answer is most likely NO. The results of large- scale randomized trials in the once two decades have shown that for the maturity of the population, MVM supplements aren't only ineffective, but they may be injurious to health [1].

When the nascence-Tocopherol Beta-Carotene Cancer Prevention (ATBC) study presented the first strong substantiation for a dangerous effect of vitamins in 1994 health scientists were caught by surprise. The results of this large-scale 2 × 2 factorial design trial, which randomized over, 000 middleaged Finnish smoker men to admit α- tocopherol (a form of vitamin E), betacarotene (a precursor of vitamin A), both, or neither, showed that β-carotene statistically significantly increased lung cancer prevalence by 18 and total mortality by 8, substantially due to increased deaths from lung cancer and ischemic cardiac complaint. α-tocopherol didn't materially change the threat of lung cancer or total deaths [2].

Despite the strong design of this trial and its large sample size, the results were met with dubitation. The results were supposed to be inconsistent with several of the preliminarily published experimental studies, grounded on which the trial had been designed to reduce the threat of lung cancer. Several of the accompanying letters of correspondence, published in the New England Journal of Medicine, refocused to the implicit failings of this study, similar as short duration of the study (i.e., a standard follow- up of six times). Nonetheless, results of utmost of the posterior trials, using other forms of vitamins and supplements, conducted in different populations and with different durations of use, have verified no benefit or indeed harm from the use of similar vitamin supplements [3,4].

The most recent notable bone was the Selenium and Vitamin E Cancer Prevention Trial (elect Trial), the extended results of which showed that vitamin E supplements could increase the threat of prostate cancer among healthy men. One exception to these null or injurious goods was the result of the General Population Nutrition Intervention Trial conducted in Linxian, China, which tested four combinations of vitamins and supplements (videlicet, factors A, B, C, and D). Factor D (a combination of selenium, α-tocopherol, and β-carotene) reduced overall mortality by roughly 10. Still, this trial was conducted in an area where micronutrient input was relatively poor, and therefore supplements might have had a salutary part. Indeed in this nutritiondeficient population, results of the trial showed no benefit for two of the other MVM supplements and extended follow- up showed adverse results for one of the supplements [5].

Conclusion

In summary, although in the long run MVMs may slightly increase the threat of cancer and cardiovascular conditions, in the short run they produce little detriment or no detriment, and therefore negative consequences won't be perceptible by individualities taking them. MVM deals benefit from misleading commercials, and people are pleased by the well- known placebo goods. Thus, Americans who have been using MVMs since the early 1940s will most probably continue to use them in the foreseeable future, and the rest of the world will follow.

References

1. Bailey, Regan L., Jody S. Engel, Paul R. Thomas and Mary Frances Picciano. "Dietary supplement use in the United States, 2003â??2006." J Nutr 141 (2011): 261-266.

Google Scholar, Indexed at, Crossref

2. Omenn, Gilbert S., Gary E. Goodman, Andrew Glass and James P. Keogh et al. "Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease." N Engl J Med 334 (1996): 1150-1155.

Google Scholar, Indexed at, Crossref

3. Hennekens, Charles H., Joann E. Manson, Nancy R. Cook and Charlene Belanger, et al. "Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease." N Engl J Med 334 (1996): 1145-1149.

Google Scholar, Indexed at, Crossref

4. Meyer, François, Pierre Douville, Sandrine Bertrais and Serge Hercberg. "Antioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU. VI. MAX trial." Int J Cancer 116 (2005): 182-186.

Google Scholar, Indexed at, Crossref

5. Creagan, Edward T., Judith R. O'Fallon, Joseph Rubin and Stephen Frytak et al. "Failure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial." N Engl J Med 301 (1979): 687-690.

Google Scholar, Indexed at, Crossref